NSRX

Nasus Pharma Ltd NSRX

NYSESmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 10 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$1.24B

Quarter to Dec 31

Net income

$-5.86M

Quarter to Dec 31

Free cash flow

$-4.93M

Quarter to Dec 31

Operating margin

-0.4%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$7.53M total
BALYASNY ASSET MANAGEMENT L.P.
$3.14M0.0%
Cable Car Capital, LP
$2.16M+2.3%
Velan Capital Investment Management LP
$1.26M0.0%
Hudson Bay Capital Management LP
$471.7K0.0%
Bleichroeder LP
$314.5K0.0%
CITADEL ADVISORS LLC
$77.0KNew
XTX Topco Ltd
$58.2KNew
RENAISSANCE TECHNOLOGIES LLC
$42.7KNew
MORGAN STANLEY
$3.5K-50.0%
Caitong International Asset Management Co., Ltd
$14New
See all 10 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

NSRX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Nasus Pharma Ltd's annual filings on SEC EDGAR.

Nasus Pharma Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$1.2B$-5.9M-0.4%
Source: NSRX filings on SEC EDGAR →

NSRX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Nasus Pharma Ltd (NSRX): stock profile, AI score and financials

Nasus Pharma Ltd (NSRX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NSRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 10 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Nasus Pharma Ltd reports quarterly revenue of $1.2B, net income of $-5.9M, an operating margin of -0.4%. Top institutional holders of NSRX by reported 13-F value include BALYASNY ASSET MANAGEMENT L.P., Cable Car Capital, Velan Capital Investment Management, based on the most recent SEC filings. NSRX trades on the NYSE exchange and files with the SEC under CIK 2029039. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NSRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Nasus Pharma Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 2029039 →